Lafayette, R. Et Al. 2024. WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL. KIDNEY INTERNATIONAL REPORTS , vol.9, no.4 , 173-174.

Lafayette, R., Kristensen, J., Stone, A., Floege, J., Tesař, V., Trimarchi, H., ... Zhang, H.(2024). WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL. KIDNEY INTERNATIONAL REPORTS , vol.9, no.4, 173-174.

Lafayette, Richard Et Al. "WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL," KIDNEY INTERNATIONAL REPORTS , vol.9, no.4, 173-174, 2024

Lafayette, Richard Et Al. "WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL." KIDNEY INTERNATIONAL REPORTS , vol.9, no.4, pp.173-174, 2024

Lafayette, R. Et Al. (2024) . "WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL." KIDNEY INTERNATIONAL REPORTS , vol.9, no.4, pp.173-174.

@article{article, author={Richard Lafayette Et Al. }, title={WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL}, journal={KIDNEY INTERNATIONAL REPORTS}, year=2024, pages={173-174} }